Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Eubel Brady & Suttman Asset Management Inc.

Eubel Brady & Suttman Asset Management Inc. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 233,456 shares of the medical equipment provider’s stock after acquiring an additional 3,128 shares during the quarter. Zimmer Biomet comprises about 3.3% of Eubel Brady & Suttman Asset Management Inc.’s investment portfolio, making the stock its 8th biggest holding. Eubel Brady & Suttman Asset Management Inc. owned 0.12% of Zimmer Biomet worth $24,660,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Dunhill Financial LLC boosted its stake in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet during the third quarter worth about $28,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet in the third quarter worth about $35,000. Finally, Kentucky Trust Co acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $39,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent research reports. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James cut their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $104.89 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The business’s 50-day moving average price is $105.86 and its two-hundred day moving average price is $107.47. The company has a market capitalization of $20.88 billion, a P/E ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 earnings per share. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.